Skip to main content

Childhood Mortality clinical trials at UCSF
2 in progress, 0 open to eligible people

  • Mortality Reduction After Oral Azithromycin Contingency: Mortality Study

    Sorry, not currently recruiting here

    MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality. All communities were subsequently treated with mass azithromycin for one year. The present trial re-randomized communities to azithromycin or placebo for the fourth and fifth year of the study.

    San Francisco, California and other locations

  • Mortality Reduction After Oral Azithromycin: Morbidity Study

    Sorry, accepting new patients by invitation only

    The long-term goal of this study is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood morbidity and increasing growth, and for the potential selection of antibiotic resistance. The investigators propose a set of 3 cluster-randomized trials in Malawi, Niger, and Tanzania comparing communities randomized to oral azithromycin with those randomized to placebo. To assess the generalizability of the intervention, investigators will monitor for antibiotic resistance, which could potentially limit adoption of mass antibiotic treatments. The investigators will also assess several measures of infectious diseases. The investigators hypothesize that mass azithromycin treatments will reduce childhood morbidity and will be accompanied by an acceptable level of antibiotic resistance.

    San Francisco, California and other locations

Last updated: